Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.
Colorectal Cancer
BIOLOGICAL: cetuximab|DRUG: oxaliplatin|DRUG: leucovorin|DRUG: 5-fluorouracil|DRUG: 5-fluorouracil|BIOLOGICAL: cetuximab
Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone., Every six weeks
Compare the response rates between the two treatment arms., Every six weeks|Compare progression-free survival between the two treatment arms., Every six weeks|Duration of response within each treatment arm., Every six weeks|Time to response within each treatment arm., Every six weeks|Compare the safety profiles between the two treatment arms., Every six weeks|Compare the quality of life (QOL)between the two treatment arms., Every six weeks|Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms., Every six weeks
The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.